论文部分内容阅读
目的 :为了进一步探讨泵雾化吸入皮质激素和支气管扩张剂治疗哮喘急性发作的临床效果。方法 :对我院 74例临床诊断哮喘病的患儿应用布地奈德混悬液联合博利康尼令舒泵雾化吸入与静点激素加支气管扩张剂治疗小儿哮喘急性发作进行对比研究。其中观察组 40例 ,对照组 34例。结果 :观察组给予泵雾化吸入布地奈德混悬液和博利康尼令舒治疗后 ,其呼吸困难、喘息、肺部哮喘音、咳嗽消失的天数及平均住院天数均较静脉点滴激素和支气管扩张剂的对照组明显缩短 (P <0 0 5)。治疗效果 ,观察组显效 2 0例 (45 45 % ) ,有效 2 3例 (52 2 7% ) ,无效 1例 (2 2 8% ) ,总有效率 97 72 %。对照组显效 6例 (2 0 % ) ,有效 1 3例 (43 33 % ) ,无效 1 1例 (36 67% ) ,总有效率 63 33 %两组差异有高度显著性(P <0 0 5)。结论 :布地奈德混悬液和博利康尼雾化液联合应用治疗小儿哮喘急性发作起效迅速、疗效确切、安全、副作用小、患者依从性好 ,值得临床推广应用
OBJECTIVE: To further investigate the clinical effect of inhalation of corticosteroids and bronchodilators by pumps on asthma exacerbations. Methods: In our hospital, 74 cases of clinical diagnosis of asthma in children with budesonide suspension combined with boli Kang Ni Shu pump atomization inhalation and intravenous hormone plus bronchodilator treatment of acute asthma in children were compared. 40 cases in the observation group and 34 cases in the control group. Results: Compared with intravenous drip hormone and bronchodilation, the observation group was given pump inhalation of budesonide suspension and bevacizidine, and their dyspnea, wheezing, lung asthma tone, days of cough disappearing and average days of hospitalization The control group was significantly shorter (P <0.05). The therapeutic effect was observed in 20 cases (45 45%) in the observation group, 23 cases (52 2 7%) effective, 1 case (2 28%) ineffective, and the total effective rate was 97 72%. There were 6 cases (20%) in the control group, 13 cases (43.33%) effective and 1 (36.67%) ineffective, with a total effective rate of 63.33% (P <0.05 ). Conclusion: Combination of Budesonide suspension and Boli Kang Ni atomized liquid in the treatment of children with acute attack of acute onset of rapid onset, effective, safe, small side effects, patient compliance is good, worthy of clinical application